Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.…
Belite Bio (BLTE) Q3 2026 Earnings Call Transcript
Belite Bio (NASDAQ: BLTE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 41 employees.
The shares were at 127.38 USD on 20 November 2026, up 12.5% over 52 weeks. Its 52-week range is 102.00 USD to 200.00 USD: the price is 36.3% below the high and 24.9% above the low.
Its market capitalisation is 5.17B USD.
Belite Bio reports return on equity of -10.1% and an operating margin of 0.0%.
Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 233.00 USD is 82.9% above the current price. The next earnings report is expected on 1 March 2027.